Announcements Trials
Browse Landscape

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Thrombosis 1Polycythemia Vera 1Polycythemia 1Neoplasms 1Carcinoma, Squamous Cell 1Adenocarcinoma 1

Interventions

Gemcitabine 8Capecitabine 6pembrolizumab 5Carboplatin 5Pemetrexed 3Paclitaxel 3Oxaliplatin 3Irinotecan 3regorafenib 2osimertinib 2Taxes 2Sunitinib 2Radiotherapy 2Fluorouracil 2Cisplatin 2130-nm albumin-bound paclitaxel 2trifluridine tipiracil drug combination 1tislelizumab 1tegafur-gimeracil-oteracil 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1sintilimab 1seribantumab 1selinexor 1ruxolitinib 1rubitecan 1pralsetinib 1palbociclib 1olaparib 1niraparib 1linifanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Adenocarcinoma × Phlebotomy × Clear all
NCT00507702 2019-04-18

Identification of Key Blood Molecular Markers for Immunotherapy

Stanford University

Terminated
191 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Squamous Cell, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡